Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice

Journal of Surgical Research

Volumn 172, Issue 1, 2012, Pages 116-122

  Nonaka, Koichi ^a   Onizuka, Shinya ^a   Ishibashi, Hiromi ^a   Uto, Yoshihiro ^b   Hori, Hitoshi ^b   Nakayama, Toshiyuki ^a   Matsuura, Nariaki ^c   Kanematsu, Takashi ^a   Fujioka, Hikaru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

anti angiogenesis; DBP maf; HCC; macrophage; SCID mouse

Indexed keywords

MACROPHAGE ACTIVATING FACTOR; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; LIVER NEOPLASMS; MACROPHAGE-ACTIVATING FACTORS; MACROPHAGES; MALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PHAGOCYTOSIS; RATS; VITAMIN D-BINDING PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82955213910     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.07.057     Document Type: Article

References (34)

1. S. Caldwell, and S.H. Park The epidemiology of hepatocellular cancer: From the perspectives of public health problem to tumor biology J Gastroenterol 44 Suppl 19 2009 96
2. X.P. Chen, F.Z. Qiu, and Z.D. Wu Long-term outcome of resection of large hepatocellular carcinoma Br J Surg 93 2006 600
3. S.R. Knight, P.J. Friend, and P.J. Morris Role of transplantation in the management of hepatic malignancy Br J Surg 94 2007 1319
4. K. Kobayashi, H. Fujioka, and K. Yanaga Underlying histological activity of hepatitis plays an important role for tumor recurrence after curative resection of hepatocellular carcinoma Acta Medica Nagasakiensia 53 2009 97
5. M.A. Zimmerman, R.M. Ghobrial, and M.J. Tong Recurrence of hepatocellular carcinoma following liver transplantation: A review of preoperative and postoperative prognostic indicators Arch Surg 143 2008 182 discussion 188
6. B. Rampone, B. Schiavone, and A. Martino Current management strategy of hepatocellular carcinoma World J Gastroenterol 15 2009 3210
7. C.Y. Li, S. Shan, and Q. Huang Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models J Natl Cancer Inst 92 2000 143
8. J. Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182
9. Y. Ishii, T. Sakamoto, and R. Ito Anti-angiogenic therapy on hepatocellular carcinoma development and progression J Surg Res 2008
10. O. Kisker, S. Onizuka, and C.M. Becker Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice Neoplasia 5 2003 32
11. N. Yamamoto, and V.R. Naraparaju Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor Cancer Res 57 1997 2187
12. H. Nagasawa, Y. Uto, and H. Sasaki Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity Anticancer Res 25 2005 3689
13. R.P. Link, K.L. Perlman, and E.A. Pierce Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography Anal Biochem 157 1986 262
14. N. Yamamoto, and S. Homma Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes Proc Natl Acad Sci USA 88 1991 8539
15. M.J. Bissell Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol 155 1999 675
16. B. Jiang, S. Morimoto, and J. Yang Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells J Cardiovasc Pharmacol 31 Suppl 1 1998 S142
17. J.R. Merchan, B. Chan, and S. Kale In vitro and in vivo induction of anti-angiogenic activity by plasminogen activators and captopril J Natl Cancer Inst 95 2003 388
18. S. Onizuka, S. Kawakami, and K. Taniguchi Pancreatic carcinogenesis: Apoptosis and angiogenesis Pancreas 28 2004 317
19. N. Weidner Intratumor microvessel density as a prognostic factor in cancer Am J Pathol 147 1995 9
20. A.J. McKnight, A.J. Macfarlane, and P. Dri Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family J Biol Chem 271 1996 486
21. S. Kanda, Y. Mochizuki, and Y. Miyata Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis J Natl Cancer Inst 94 2002 1311
22. S. Kalkunte, L. Brard, and C.O. Granai Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf Angiogenesis 8 2005 349
23. R. Yamaguchi, H. Yano, and A. Iemura Expression of vascular endothelial growth factor in human hepatocellular carcinoma Hepatology 28 1998 68
24. L. Messerini, L. Novelli, and C.E. Comin Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma J Clin Pathol 57 2004 867
25. J.A. Sparano, R. Gray, and B. Giantonio Evaluating antiangiogenesis agents in the clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials Clin Cancer Res 10 2004 1206
26. A.B. Siegel, E.I. Cohen, and A. Ocean Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992
27. M.B. Thomas, J.S. Morris, and R. Chadha Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma J Clin Oncol 27 2009 843
28. T. Tsuchiyama, Y. Nakamoto, and Y. Sakai Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation Cancer Sci 99 2008 2075
29. Y.W. Li, S.J. Qiu, and J. Fan Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection J Cancer Res Clin Oncol 135 2009 439
30. C.Y. Lin, C.J. Lin, and K.H. Chen Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction FEBS Lett 580 2006 3042
31. A. Mantovani, S. Sozzani, and M. Locati Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol 23 2002 549
32. S.B. Mohamad, H. Nagasawa, and H. Sasaki Gc protein-derived macrophage activating factor (GcMAF): Isoelectric focusing pattern and tumoricidal activity Anticancer Res 23 2003 4451
33. M.S. O'Reilly, L. Holmgren, and C. Chen Angiostatin induces and sustains dormancy of human primary tumors in mice Nat Med 2 1996 689
34. T. Boehm, J. Folkman, and T. Browder Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 1997 404